A phase 2 study of neoadjuvant systemic therapy with eribulin followed by doxorubicin and cyclophosphamide for HER2-negative inflammatory breast cancer

被引：1
|
作者：
Lynce, Filipa
Yeh, Eren D.
Regan, Meredith M.
Qin, Lei
Bay, Camden P.
Krop, Ian
Harrison, Beth T.
Nakhlis, Faina
Bellon, Jennifer
Overmoyer, Beth
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-P2-12-18
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-12-18
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Biomarkers of neoadjuvant/adjuvant endocrine therapy for ER-positive/HER2-negative breast cancer
    Ueno, Takayuki
    CHINESE CLINICAL ONCOLOGY, 2020, 9 (03)
  • [42] Eribulin combined with antiangiogenic agents in women with HER2-negative metastatic breast cancer: a retrospective multicenter study
    Jiang, Mingxia
    Shao, Bin
    Wan, Donggui
    Liu, Jiaxuan
    He, Maiyue
    Chai, Yue
    Sang, Die
    Wang, Jiayu
    Ma, Fei
    Fan, Ying
    Yuan, Peng
    Xu, Binghe
    Li, Qiao
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [43] Results of a Phase Ib Study Investigating Durvalumab in Combination with Eribulin in Patients with HER2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer
    Landry, Chrystal A.
    Blanter, Julia
    Ru, Meng
    Fasano, Julie
    Klein, Paula
    Shao, Theresa
    Bhardwaj, Aarti
    Tiersten, Amy
    ONCOLOGY, 2023,
  • [44] Results of a Phase Ib Study Investigating Durvalumab in Combination with Eribulin in Patients with HER2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer
    Landry, Chrystal A.
    Blanter, Julia
    Ru, Meng
    Fasano, Julie
    Klein, Paula
    Shao, Theresa
    Bhardwaj, Aarti
    Tiersten, Amy
    ONCOLOGY, 2023,
  • [45] Results of a Phase Ib Study Investigating Durvalumab in Combination with Eribulin in Patients with HER2-Negative Metastatic Breast Cancer and Recurrent Ovarian Cancer
    Landry, Chrystal A.
    Blanter, Julia
    Ru, Meng
    Fasano, Julie
    Klein, Paula
    Shao, Theresa
    Bhardwaj, Aarti
    Tiersten, Amy
    ONCOLOGY, 2024, 102 (01) : 9 - 16
  • [46] Eribulin combined with anlotinib for patients with HER2-negative metastatic breast cancer: A single-arm, multicenter, phase II study
    Yin, Y.
    Wu, X.
    Huang, X.
    Li, W.
    Hua, Y.
    Liang, Y.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S648 - S649
  • [47] Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer
    Matsuda, Naoko
    Wang, Xiaoping
    Lim, Bora
    Krishnamurthy, Savitri
    Alvarez, Ricardo H.
    Willey, Jie S.
    Parker, Charla A.
    Song, Juhee
    Shen, Yu
    Hu, Jianhua
    Wu, Wenhui
    Li, Nan
    Babiera, Gildy V.
    Murray, James L.
    Arun, Banu K.
    Brewster, Abenaa M.
    Reuben, James M.
    Stauder, Michael C.
    Barnett, Chad M.
    Woodward, Wendy A.
    Le-Petross, H. T. Carisa
    Lucci, Anthony
    DeSnyder, Sarah M.
    Tripathy, Debu
    Valero, Vicente
    Ueno, Naoto T.
    JAMA ONCOLOGY, 2018, 4 (09) : 1207 - 1213
  • [48] First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study
    Hardy-Bessard, Anne-Claire
    Brocard, Fabien
    Clatot, Florian
    Lortholary, Alain
    You, Benoit
    Grenier, Julien
    Martin-Babau, Jerome
    Lucas, Brigitte
    Meunier, Jerome
    Ferrero, Jean-Marc
    Savoye, Aude-Marie
    Marti, Adina
    Despax, Raymond
    Moullet, Isabelle
    Emile, George
    BREAST, 2020, 54 : 256 - 263
  • [49] Phase Ib Clinical and Pharmacodynamic Study of the TIE2 Kinase Inhibitor Rebastinib with Paclitaxel or Eribulin in HER2-Negative Metastatic Breast Cancer
    Anampa, Jesus D.
    Flynn, Daniel L.
    Leary, Cynthia
    Oh, Sun
    Xue, Xiaonan
    Oktay, Maja H.
    Condeelis, John S.
    Sparano, Joseph A.
    CLINICAL CANCER RESEARCH, 2025, 31 (02) : 266 - 277
  • [50] Results of a phase 2, multicenter, single-arm study of eribulin mesylate as first-line therapy for locally recurrent or metastatic HER2-negative breast cancer
    Vandat, L.
    Schwartzberg, L.
    Gluck, S.
    Rege, J.
    Liao, J.
    Cox, D.
    O'Shaughnessy, J.
    CANCER RESEARCH, 2012, 72
12345